Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cosmos Health Inc COSM

Healthcare
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals... see more

Recent & Breaking News (NDAQ:COSM)

Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price

Accesswire 21 hours ago

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Accesswire 8 days ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ

Accesswire 12 days ago

Cosmos Health Issues Letter to Shareholders

Accesswire November 12, 2024

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

Accesswire November 1, 2024

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

Accesswire September 25, 2024

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

Accesswire September 23, 2024

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Accesswire September 23, 2024

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Accesswire September 19, 2024

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Accesswire September 18, 2024

Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price

Accesswire September 17, 2024

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

PR Newswire September 16, 2024

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Accesswire September 16, 2024

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Accesswire August 23, 2024

Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE

Accesswire August 21, 2024

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

Accesswire August 21, 2024

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023

Accesswire August 20, 2024

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

Accesswire August 20, 2024

Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market

Accesswire August 8, 2024

Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share

Accesswire August 6, 2024